Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-09-27
2008-09-16
Saunders, David A. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C514S002600, C514S866000, C514S885000, C514S886000, C514S903000, C424S278100, C424S280100, C424S810000, C530S350000
Reexamination Certificate
active
07425332
ABSTRACT:
The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 4594409 (1986-06-01), Hayashi et al.
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter et al.
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5668117 (1997-09-01), Shapiro et al.
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958972 (1999-09-01), Hupe et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Rodriguez et al.
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7022663 (2006-04-01), Gilbert et al.
patent: 7033582 (2006-04-01), Yong et al.
patent: 7074580 (2006-07-01), Gad et al.
patent: 7163802 (2007-01-01), Gad et al.
patent: 7199098 (2007-04-01), Konfino et al.
patent: 7279172 (2007-10-01), Aharoni et al.
patent: 2002/0037848 (2002-03-01), Eisenbach-Schwart et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2002/0077278 (2002-06-01), Yong et al.
patent: 2002/0107388 (2002-08-01), Vandenbark
patent: 2003/0004099 (2003-01-01), Eisenbach-Schwartz et al.
patent: 2003/0170729 (2003-09-01), Strominger et al.
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2005/0019322 (2005-01-01), Rodriguez et al.
patent: 2005/0170004 (2005-08-01), Rosenberger
patent: 2005/0171286 (2005-08-01), Konfino et al.
patent: 2005/0256046 (2005-11-01), Gad et al.
patent: 2006/0052586 (2006-03-01), Dolitzky
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 2007/0007055 (2007-01-01), Rosenberger et al.
patent: 2007/0021324 (2007-01-01), Dolitzky et al.
patent: 2007/0048794 (2007-03-01), Gad et al.
patent: 2007/0054857 (2007-03-01), Pinchasi et al.
patent: 3930733 (1991-03-01), None
patent: 0378246 (1990-06-01), None
patent: 0383620 (1990-08-01), None
patent: 0359783 (1995-11-01), None
patent: 1292279 (2003-03-01), None
patent: 0254496 (1990-08-01), None
patent: 0336690 (1998-01-01), None
patent: 1690368 (1995-08-01), None
patent: 1469826 (1995-11-01), None
patent: 1182051 (1985-09-01), None
patent: 1664845 (1991-07-01), None
patent: 8810120 (1988-12-01), None
patent: 9202543 (1992-02-01), None
patent: 9403484 (1994-02-01), None
patent: 9426774 (1994-11-01), None
patent: 9526980 (1995-10-01), None
patent: 9531990 (1995-11-01), None
patent: 9531997 (1995-11-01), None
patent: 9533475 (1995-12-01), None
patent: 9830227 (1998-07-01), None
patent: 0005250 (2000-02-01), None
patent: 0005249 (2000-03-01), None
patent: 0018794 (2000-04-01), None
patent: 0020010 (2000-04-01), None
patent: 0027417 (2000-05-01), None
patent: 0152878 (2001-07-01), None
patent: 0160392 (2001-08-01), None
patent: 0185797 (2001-11-01), None
patent: 0193828 (2001-12-01), None
patent: 0193893 (2001-12-01), None
patent: 02076503 (2002-10-01), None
patent: 03048735 (2003-06-01), None
patent: 0197846 (2004-12-01), None
patent: 0980214 (1999-09-01), None
Tisch, R et al. Proc. Nat. Acad. Sci. (USA). [1994]91:437-438.
Abramsky, et al., “Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis”,J. Neurol. Sci., 1977, 31, 433-438.
Aharoni, et al., “T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis”,Eur. J. Immunol., 1993, 23, 17-25.
Aharoni, et al., “Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease”,Immunol. Letters, 1997, 58, 79-87.
Aharoni, et al., “Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis”,Proc. Natl. Acad. Sci. USA, 1997, 94, 10821-10826.
Aharoni, et al., “Cop 1 Specific Supporessor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151”, Neurology, 1997, vol. 48, No. 3, A422.
Aharoni, et al., “Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1”,Journal of Neuroimmunology, 1998, 91, 135-146.
Alvord, et al., “Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys”,Ann. Neurol., 1979, 6, 469-473.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen”,Israel J. Med. Sci., 8, 1759-1760.
Arnon, et al., “Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids”,Neurol., 1978, 28, 336 (Abstract).
Arnon, et al., “Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues” inThe Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis(Academic Press, New York, 1980) 105-107.
Arnon. “A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy” inProgress in Multiple Sclerosis Research(Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418.
Arnon. “Experimental Allergic Encephalomyelitis—Susceptibility and Suppression”,Immunological Rev., 1981, 55, 5-30.
Arnon, et al., “Suppression of Demyelinating Diseases by Synthetic Copolymers”, inA Multidisciplinary Approach to Myelin Disease(G. Serlupi Crescenzi. ed., Plenum Publishing Corp., 1988) 243-250.
Arnon, et al., “Suppresseion of Experimental Allergic Encephalomyelitis by Cop-1—Relevance to Multiple Sclerosis”,Israel J. Med. Sci., 1989, 25, 686-689.
Arnon. et al., “Immunomodulation of Experimental Allergic Encephalomyelitis”,Israel J. Med. Sci., 1993, 29, 175-181.
Arnon, et al., “On the Existence of Suppressor Cells”,Int. Arch. Allergy Immunol., 1993, 100, 2-7.
Arnon, et al., “Immunospecific Drug Design—Prospects for Treatment of Autoimmunie Disease”,Therapeutic Immunol., 1994, 1, 65-70.
Asakura et al., “A unique population of circulating autoantibodies promotes central nervous system remyelination”,Multiple Sclerosis, 1998, 4, 217-221.
Aharoni Rina
Arnon Ruth
Fridkis-Hareli Masha
Sela Michael
Strominger Jack L.
Cooper & Dunham LLP
President and Fellows of Harvard University
Saunders David A.
VanderVegt F. Pierre
White John P.
LandOfFree
Treatment of autoimmune conditions with Copolymer 1 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of autoimmune conditions with Copolymer 1 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of autoimmune conditions with Copolymer 1 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982804